What Is Disitamab Vedotin & How Does It Work for Cancer?

Disitamab vedotin is a targeted cancer drug known as an antibody-drug conjugate, or ADC, that homes in on HER2 proteins on the surface of tumor cells and delivers a potent cell-killing chemical directly inside them. First approved in China in 2021 for advanced gastric cancer, it has since shown striking activity in bladder cancer, breast cancer, and other solid tumors, with clinical trials now running in the United States, Europe, and Asia. What makes it particularly interesting is that its design differs in meaningful ways from older HER2-targeting therapies, and emerging data suggest it can work even in tumors with relatively low levels of HER2.

How the Drug Is Designed

Like all antibody-drug conjugates, disitamab vedotin has three basic parts: an antibody that guides the drug to cancer cells, a toxic payload that does the killing, and a chemical linker that holds the two together until the right moment. The antibody component, called hertuzumab (or disitamab), targets HER2 but binds to a different spot on the receptor than trastuzumab, the antibody used in many older HER2-directed drugs. This difference gives it a stronger grip on HER2 and helps the whole conjugate get pulled inside cancer cells more efficiently.¹ Preclinical experiments have confirmed that disitamab vedotin gets internalized faster than some other HER2-targeted ADCs in certain cell lines.²

The payload is MMAE (monomethyl auristatin E), a synthetic molecule that stops cells from dividing by disrupting the tiny scaffolding structures they need to pull their chromosomes apart. MMAE is far too toxic to give on its own as a conventional chemotherapy drug. By attaching it to a HER2-seeking antibody, the idea is to concentrate most of the damage inside tumor cells while sparing healthy tissue. The linker holding everything together is a valine-citrulline peptide designed to stay intact while the drug circulates in the bloodstream but to snap apart once the conjugate reaches the acidic, enzyme-rich interior of a cancer cell’s lysosomes, releasing MMAE right where it is needed.¹

The Bystander Effect

One of the more important features of disitamab vedotin is what researchers call the “bystander killing” effect. Once MMAE is released inside a cancer cell, some of it leaks out through the cell membrane and enters neighboring tumor cells, even ones that express little or no HER2. This happens because MMAE is highly membrane-permeable. Not all ADCs can do this. Trastuzumab emtansine (T-DM1), an older HER2-targeted ADC, releases a payload that does not easily cross cell membranes, so it largely kills only the specific cell it enters. Disitamab vedotin and trastuzumab deruxtecan (T-DXd) both have cleavable linkers and membrane-permeable payloads, giving them this broader reach.³

The bystander effect matters because tumors are rarely uniform. Even in a cancer classified as “HER2-positive,” not every cell in the tumor produces the same amount of HER2 protein. Some patches may be HER2-low or even HER2-negative. A drug that can kill beyond its direct landing zone has a better shot at clearing out those mixed populations.

Results in Urothelial (Bladder) Cancer

Urothelial carcinoma, the most common type of bladder cancer, has become one of the settings where disitamab vedotin has generated the most excitement. In a combined analysis of two phase II trials involving patients whose cancer had worsened after at least one round of chemotherapy, disitamab vedotin monotherapy produced a confirmed response rate of about half, with a median progression-free survival of roughly six months and an overall survival of about 14 months.⁴ Those numbers are solid for a cancer that historically has limited options once standard chemotherapy and immunotherapy stop working.

The results got even more impressive when disitamab vedotin was combined with the immune checkpoint inhibitor toripalimab and tested head-to-head against chemotherapy in previously untreated patients. In a large randomized phase III trial, patients receiving the combination lived a median of about 31 months compared with roughly 17 months on chemotherapy. Progression-free survival more than doubled, and over three-quarters of patients in the combination group saw their tumors shrink.⁵ An earlier phase Ib/II dose-expansion study of the same combination had hinted at this, reporting a confirmed response rate of about 73% and a median overall survival exceeding 33 months.⁶

Researchers have also tested the combination before surgery in patients with muscle-invasive bladder cancer. In a real-world study of 25 patients who received disitamab vedotin plus immunotherapy as neoadjuvant treatment and then had their bladders removed, nearly half achieved a complete pathologic response, meaning no viable cancer was found in the surgical specimen. Downstaging occurred in the vast majority of patients, and all were alive at one year of follow-up.⁷

Results in Gastric Cancer

Gastric cancer, including tumors at the junction where the esophagus meets the stomach, was the first setting in which disitamab vedotin received regulatory approval. In a phase I trial combining the drug with toripalimab in HER2-expressing gastric or gastroesophageal junction cancers, about 43% of patients responded, and at the recommended phase II dose the response rate reached 50%. Median overall survival was roughly 14 to 17 months depending on the dose group, which is encouraging for heavily pretreated patients.⁸ An interesting finding from this trial was that clinical benefit appeared in both HER2-positive and HER2-low populations, suggesting the bystander effect may translate into real-world efficacy beyond classically “positive” tumors.

Real-world data have reinforced the value of pairing disitamab vedotin with immune checkpoint inhibitors in gastric cancer. A multicenter retrospective study comparing the combination with monotherapy found that adding an anti-PD-1 drug roughly tripled response rates and nearly doubled progression-free survival. The benefit was most pronounced in patients whose tumors had high HER2 expression.⁹ A separate multicenter real-world study confirmed the trend, showing better response rates and longer progression-free survival when immune checkpoint inhibitors were added, even in late-line treatment settings.¹⁰

Breast Cancer and the HER2-Low Frontier

One of the broader shifts in oncology over the past few years has been the recognition that HER2 exists on a spectrum. Tumors historically classified as “HER2-negative” can actually have low but detectable levels of HER2 protein. Drugs like trastuzumab deruxtecan (T-DXd) proved that targeting these HER2-low tumors is possible, and disitamab vedotin is now exploring the same territory.

A phase I/Ib study in advanced breast cancer tested disitamab vedotin in both HER2-overexpressing and HER2-low groups. At the recommended dose, about 43% of HER2-overexpressing patients responded, and about a third of HER2-low patients did as well. Median progression-free survival was around five to six months in both groups.¹¹ A larger multicenter retrospective analysis confirmed a difference in outcomes between the two groups but still found meaningful activity in HER2-low breast cancer, with a median progression-free survival of about 3.5 months for HER2-low patients compared with about 5.3 months for HER2-positive patients.¹²

Those numbers are modest compared with what T-DXd has shown in breast cancer, but they suggest disitamab vedotin could eventually become an additional option for patients who progress through other HER2-directed therapies. The drug’s different antibody and payload may mean its resistance profile does not perfectly overlap with that of T-DXd, potentially leaving room for sequential use.

How It Compares to Other HER2-Targeted ADCs

Three HER2-targeted ADCs now appear frequently in the cancer literature: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and disitamab vedotin. They share the same basic concept but differ in every component. T-DM1 and T-DXd both use trastuzumab as their antibody, while disitamab vedotin uses hertuzumab, which binds a different spot on HER2. All three carry different payloads: T-DM1 delivers a maytansine derivative called DM1, T-DXd delivers a topoisomerase I inhibitor called DXd, and disitamab vedotin delivers MMAE, an auristatin-based microtubule inhibitor.³

The linker chemistry also matters. T-DM1 uses a non-cleavable linker, meaning the payload stays attached to antibody fragments even after the cell digests the conjugate. T-DXd and disitamab vedotin both use cleavable linkers that release their payloads cleanly inside the cell, enabling the bystander effect described earlier. In preclinical head-to-head comparisons, disitamab vedotin showed faster internalization than both T-DM1 and T-DXd in some cancer cell lines.² Faster internalization could mean less drug is wasted sitting on the cell surface, though whether this translates into a clear clinical advantage over T-DXd in humans is still an open question.

One practical consideration is that because these three ADCs have different payloads attacking different cellular targets, resistance to one does not necessarily mean resistance to another. A tumor that has evolved to survive a topoisomerase I inhibitor might still be vulnerable to a microtubule disruptor. Researchers are already thinking about optimal sequencing strategies.

Safety and Side Effects

The side-effect profile of disitamab vedotin is driven largely by MMAE, which is what you would expect from a drug that disrupts cell division. In preclinical testing, the primary toxicities were effects on the bone marrow and blood-forming system, along with impacts on lymphoid organs like the spleen and thymus. At the same time, monkeys tolerated the full conjugate at doses of 6 mg/kg, whereas equivalent amounts of free MMAE caused severe drops in blood cell counts, a finding that supports the basic rationale of ADC design: wrapping the toxin in a targeted delivery vehicle spares the body from much of its raw destructive power.¹³

In clinical trials, the most commonly reported adverse events have been reductions in white blood cells and platelets, fatigue, and peripheral nerve numbness or tingling (peripheral neuropathy). Skin-related side effects like rash have also appeared, particularly when the drug is combined with immune checkpoint inhibitors. The combination with toripalimab in the phase III urothelial cancer trial was described as having manageable toxicity overall, though adding immunotherapy predictably introduced immune-mediated side effects like thyroid dysfunction. Most clinical reports have characterized the safety profile as acceptable for the populations being treated, which typically include patients with advanced cancers who have already been through multiple treatment lines.

Who Benefits Most

HER2 expression level is the clearest predictor of how well disitamab vedotin works. In metastatic urothelial carcinoma, a real-world multicenter study found that patients with higher HER2 expression (scored as 2+ or 3+ by immunohistochemistry) had a median progression-free survival of about 13 months and a response rate of 60%, while patients with low HER2 expression (1+) had a much shorter median progression-free survival of about 4.6 months and no confirmed responses.¹⁴ That is a striking gap and underscores the importance of accurate HER2 testing before treatment decisions are made.

The situation at the very bottom of the HER2 spectrum remains less clear. A systematic review and meta-analysis examining disitamab vedotin’s efficacy in HER2-negative and HER2-low urothelial carcinoma concluded that evidence in those populations is still limited and uncertain.¹⁵ This mirrors the broader challenge facing ADC development: the bystander effect opens the door to HER2-low tumors, but how far down the expression ladder the drug can still deliver meaningful benefit is something ongoing trials are still working out.

Other potential biomarkers are under investigation. The neoadjuvant bladder cancer study mentioned earlier found that HER2 3+ tumors were significantly more likely to achieve a complete pathologic response than tumors with lower expression levels.⁷ In gastric cancer, PD-L1 expression appears to influence the benefit of adding immunotherapy, with higher PD-L1 scores predicting better outcomes from the combination.⁹

Regulatory Status and Ongoing Trials

Disitamab vedotin received its first approval in China in June 2021 for HER2-overexpressing advanced gastric cancer after at least two prior lines of chemotherapy. Since then, its indication has expanded in China to include urothelial carcinoma. Development is also advancing in other solid tumors, including biliary tract cancer, non-small cell lung cancer, and breast cancer.¹⁶

The push into Western markets is now well underway. A large phase III trial called SGNDV-001, run in partnership with a global pharmaceutical company, is testing disitamab vedotin combined with pembrolizumab against standard chemotherapy in treatment-naive patients with HER2-expressing advanced urothelial cancer.¹⁷ If this trial confirms the results already seen in the Chinese phase III data, it could pave the way toward FDA approval and make disitamab vedotin available to patients in the United States and Europe.

The Cost Question

Even a highly effective drug has to be affordable to make a real-world difference. A formal cost-effectiveness analysis comparing disitamab vedotin plus toripalimab with standard chemotherapy in HER2-expressing urothelial cancer in China found that the combination added about 0.28 quality-adjusted life years (roughly three and a half extra months of life in good health) at an incremental cost of about $16,100. The resulting cost per quality-adjusted life year was roughly $56,900, which exceeds China’s commonly used willingness-to-pay threshold of about $38,200. Probabilistic modeling gave the combination only about a 39% chance of being considered cost-effective under current pricing.¹⁸

This does not mean the drug lacks clinical value. What it means is that, at current prices, reimbursement decisions in many health systems could be difficult. ADCs are expensive to manufacture, and combination regimens with checkpoint inhibitors double up the costs. Price negotiations, patient-assistance programs, and further data from later-line settings where alternatives are scarce could all shift the equation. For patients in countries where the drug is not yet approved, access currently depends on clinical trial enrollment or compassionate-use programs.